The stock of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) hit a new 52-week low and has $10.56 target or 4.00% below today’s $11.00 share price. The 6 months bearish chart indicates high risk for the $345.87 million company. The 1-year low was reported on Apr, 21 by Barchart.com. If the $10.56 price target is reached, the company will be worth $13.83 million less. The stock decreased 2.00% or $0.23 during the last trading session, reaching $11. About 2.44M shares traded or 352.82% up from the average. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 26.88% since April 21, 2017 and is downtrending. It has underperformed by 38.43% the S&P500.
Among 8 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Ocular Therapeutix had 25 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Buy” rating by BTIG Research on Friday, January 19. The stock has “Overweight” rating by Morgan Stanley on Thursday, February 18. The company was maintained on Tuesday, November 7 by Cantor Fitzgerald. The rating was initiated by JMP Securities on Thursday, August 11 with “Outperform”. The rating was maintained by H.C. Wainwright on Wednesday, August 9 with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, March 8. The company was maintained on Friday, March 9 by H.C. Wainwright. On Wednesday, August 2 the stock rating was maintained by BTIG Research with “Hold”. RBC Capital Markets maintained the shares of OCUL in report on Tuesday, November 15 with “Outperform” rating. As per Wednesday, August 5, the company rating was initiated by Nomura. See Ocular Therapeutix, Inc. (NASDAQ:OCUL) latest ratings:
08/03/2018 Broker: BTIG Research Rating: Buy New Target: $9.0 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $22.0 Maintain
19/01/2018 Broker: BTIG Research Old Rating: Neutral New Rating: Buy Upgrade
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $10.0 Maintain
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $21.0 Maintain
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $12.0 Initiate
The stock decreased 0.46% or $0.03 during the last trading session, reaching $6.45. About 79,556 shares traded. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 32.37% since April 21, 2017 and is downtrending. It has underperformed by 43.92% the S&P500.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $240.44 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The companyÂ’s lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Investors sentiment decreased to 0.91 in 2017 Q4. Its down 0.63, from 1.54 in 2017Q3. It dived, as 25 investors sold Paratek Pharmaceuticals, Inc. shares while 29 reduced holdings. 12 funds opened positions while 37 raised stakes. 19.34 million shares or 3.86% less from 20.11 million shares in 2017Q3 were reported. Harvest Management Ltd Limited Liability Company has invested 0.12% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Sei Invests reported 6,414 shares. Metropolitan Life Insur Company New York, a New York-based fund reported 8,135 shares. Abingworth Llp accumulated 13.5% or 1.04M shares. Raymond James Associates holds 0% or 24,157 shares. Broadfin Cap Ltd Liability Com holds 406,207 shares. 65 are held by Bankshares Of Montreal Can. Stoneridge Inv Prtnrs Limited holds 0.03% or 11,634 shares. Fortress Inv Gp holds 0.2% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 433,804 shares. Tiaa Cref Mgmt Ltd Liability Com, New York-based fund reported 91,711 shares. United Kingdom-based Glg Ptnrs L P has invested 0.16% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Water Island Limited Liability Corporation stated it has 0.2% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 308,864 were reported by General Company. Pacad Invest holds 3,800 shares. Moreover, Legal General Gp Public Ltd Company has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $345.87 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.